Amedisys, Inc. (NASDAQ:AMED) today reported its financial results
for the three month period and year ended December 31, 2017.
Three Month Periods Ended December 31, 2017 and 2016
- Net service revenue increased $37.9 million to
$404.2 million compared to $366.3 million in 2016.
- Net loss attributable to Amedisys, Inc. of $3.8 million
which is inclusive of a $21.4 million reduction in net income
as a result of the enactment of H.R. 1 (Tax Cuts and Jobs Act),
compared to net income attributable to Amedisys, Inc. of
$8.9 million in 2016.
- Net loss attributable to Amedisys, Inc. per diluted share of
$0.11 compared to net income attributable to Amedisys, Inc. of
$0.26 in 2016.
Adjusted Quarterly Results*
- Adjusted EBITDA of $37.1 million compared to
$30.5 million in 2016.
- Adjusted net service revenue of $404.2 million compared to
$365.1 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. of
$19.4 million compared to $15.0 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. per diluted
share of $0.56 compared to $0.44 in 2016.
Years Ended December 31, 2017 and 2016
- Net service revenue increased $96.2 million to
$1,533.7 million compared to $1,437.4 million in
2016.
- Net income attributable to Amedisys, Inc. of $30.3 million
which is inclusive of a $21.4 million reduction in net income as a
result of the enactment of H.R. 1 (Tax Cuts and Jobs Act), compared
to $37.3 million in 2016.
- Net income attributable to Amedisys, Inc. per diluted share of
$0.88 compared to $1.10 in 2016.
Adjusted Year End Results*
- Adjusted EBITDA of $142.2 million compared to
$109.9 million in 2016.
- Adjusted net service revenue of $1,540.2 million compared
to $1,437.3 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. of
$75.9 million compared to $52.2 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. per diluted
share of $2.21 compared to $1.55 in 2016.
* See pages 12 and 13 for the definition and
reconciliations of non-GAAP financial measures to GAAP
measures.
Paul B. Kusserow, President and Chief Executive Officer stated,
“I am extremely pleased with the results that our team delivered
during the fourth quarter and in 2017. We demonstrated solid
growth across all three line of business, continued to improve our
position as an industry leader in clinical quality and realized the
efficiencies that we promised to our stakeholders in early 2016;
all of which helped deliver significant increases in revenue,
EBITDA and earnings per share. Entering 2018, we remain focused on
our four strategic areas of focus: clinical distinction, employer
of choice, operational efficiency and driving growth. As a result
of our efforts in the last few years, we have a strong balance
sheet and will look to deploy capital to expand our businesses and
continue our dedication to deliver value to our patients, referral
sources, and, ultimately, our shareholders.”
2018 Guidance
- Net service revenue is anticipated to be in the range of
$1.60 billion to $1.64 billion.
- Adjusted EBITDA is anticipated to be in the range of
$158 million to $163 million.
- Adjusted diluted earnings per share is anticipated to be in the
range of $2.97 to $3.08 based on an estimated 34.85 million shares
outstanding.
This guidance excludes the effects of any future acquisitions,
if any are made.
We urge caution in considering the current trends and 2018
guidance disclosed in this press release. The home health and
hospice industry is highly competitive and subject to intensive
regulations, and trends and guidance are subject to numerous
factors, risks, and uncertainties, some of which are referenced in
the cautionary language below and others that are described more
fully in our reports filed with the Securities and Exchange
Commission (“SEC”) including our Annual Report on Form 10-K for the
fiscal year ended December 31, 2017, and subsequent Quarterly
Reports on Form 10-Q, and current reports on Form 8-K which can be
found on the SEC’s internet website, http://www.sec.gov, and our
internet website, http://www.amedisys.com.
Earnings Call and Webcast Information
Amedisys will host a conference call on Wednesday,
February 28, 2018, at 12:00 p.m. ET to discuss its fourth
quarter and year end results. To participate on the conference
call, please call before 12:00 p.m. ET to either (877) 524-8416
(Toll-Free) or (412) 902-1028 (Toll). A replay of the conference
call will be available through March 28, 2018 by dialing (877)
660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering
conference ID #13676051.
A live webcast of the call will be accessible through our
website on our Investor Relations section at the following web
address: http://investors.amedisys.com.
Non-GAAP Financial Measures
This press release includes reconciliations of the most
comparable financial measures calculated and presented in
accordance with accounting principles generally accepted in the
U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP
financial measures as defined under SEC rules are as follows:
(1) adjusted EBITDA, defined as net income (loss) attributable
to Amedisys, Inc. before provision for income taxes, net interest
expense and depreciation and amortization, excluding certain items;
(2) adjusted net service revenue, defined as net service
revenue excluding certain items; (3) adjusted net income
attributable to Amedisys, Inc., defined as net income (loss)
attributable to Amedisys, Inc. excluding certain items; and
(4) adjusted net income attributable to Amedisys, Inc. per
diluted share, defined as net income (loss) attributable to
Amedisys, Inc. common stockholders per diluted share excluding
certain items. Management believes that these non-GAAP financial
measures, when reviewed in conjunction with GAAP financial
measures, are useful gauges of our current performance and are also
included in internal management reporting. These non-GAAP financial
measures should be considered in addition to, and not more
meaningful than or as an alternative to the GAAP financial measures
presented in this earnings release and the company’s financial
statements. Non-GAAP measures as presented herein may not be
comparable to similarly titled measures reported by other companies
since not all companies calculate these non-GAAP measures
consistently.
Additional information
Amedisys, Inc. (the “Company”) is a leading healthcare at home
Company delivering personalized home health, hospice and personal
care. Amedisys is focused on delivering the care that is best for
our patients, whether that is home-based personal care; recovery
and rehabilitation after an operation or injury; care focused on
empowering them to manage a chronic disease; or hospice care at the
end of life. More than 3,000 hospitals and 59,000 physicians
nationwide have chosen Amedisys as a partner in post-acute care.
Founded in 1982, headquartered in Baton Rouge, LA with an executive
office in Nashville, TN, Amedisys is a publicly held company. With
17,900 employees, in 421 care centers in 34 states and the District
of Columbia, Amedisys is dedicated to delivering the highest
quality of care to the doorsteps of more than 369,000 patients in
need every year. For more information about the Company, please
visit: www.amedisys.com.
We use our website as a channel of distribution for important
company information. Important information, including press
releases, investor presentations and financial information
regarding our company, is routinely posted on and accessible on the
Investor Relations subpage of our website, which is accessible by
clicking on the tab labeled “Investors” on our website home page.
Visitors to our website can also register to receive automatic
e-mail and other notifications alerting them when new information
is made available on the Investor Relations subpage of our
website.
Forward-Looking Statements
When included in this press release, words like “believes,”
“belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,”
“estimates,” “may,” “might,” “would,” “should” and similar
expressions are intended to identify forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
These forward-looking statements involve a variety of risks and
uncertainties that could cause actual results to differ materially
from those described therein. These risks and uncertainties
include, but are not limited to the following: changes in Medicare
and other medical payment levels, our ability to open care centers,
acquire additional care centers and integrate and operate these
care centers effectively, changes in or our failure to comply with
existing federal and state laws or regulations or the inability to
comply with new government regulations on a timely basis,
competition in the healthcare industry, our ability to integrate
our personal care segment into our business efficiently, changes in
the case mix of patients and payment methodologies, changes in
estimates and judgments associated with critical accounting
policies, our ability to maintain or establish new patient referral
sources, our ability to attract and retain qualified personnel,
changes in payments and covered services by federal and state
governments, future cost containment initiatives undertaken by
third-party payors, our access to financing, our ability to meet
debt service requirements and comply with covenants in debt
agreements, business disruptions due to natural disasters or acts
of terrorism, our ability to integrate, manage and keep our
information systems secure, our ability to comply with requirements
stipulated in our corporate integrity agreement and changes in law
or developments with respect to any litigation relating to the
Company, including various other matters, many of which are beyond
our control.
Because forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified, you should not rely on any forward-looking statement as
a prediction of future events. We expressly disclaim any obligation
or undertaking and we do not intend to release publicly any updates
or changes in our expectations concerning the forward-looking
statements or any changes in events, conditions or circumstances
upon which any forward-looking statement may be based, except as
required by law.
|
|
|
Contact: |
Investor
Contact: |
Media
Contact: |
|
Amedisys,
Inc. |
Amedisys,
Inc. |
|
David
Castille |
Kendra
Kimmons |
|
Managing Director, Treasury/Finance |
Vice President,
Marketing & Communications |
|
(855)
259-2046 |
(225)
299-3720 |
|
IR@amedisys.com |
kendra.kimmons@amedisys.com |
|
|
|
AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS
(Amounts in thousands, except per share data)
|
|
|
|
|
|
For the Three Month Period
Ended December 31, |
|
|
For the Year Ended
December 31, |
|
|
2017 |
|
2016 |
|
|
2017 |
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
|
Net service
revenue |
$ |
404,238 |
|
$ |
366,296 |
|
|
$ |
1,533,680 |
|
$ |
1,437,454 |
|
Cost of service,
excluding depreciation and amortization |
|
238,534 |
|
|
212,589 |
|
|
|
900,726 |
|
|
833,055 |
|
General and
administrative expenses: |
|
|
|
|
Salaries
and benefits |
|
79,406 |
|
|
75,902 |
|
|
|
305,938 |
|
|
306,981 |
|
Non-cash
compensation |
|
4,507 |
|
|
3,845 |
|
|
|
16,295 |
|
|
16,401 |
|
Other |
|
39,757 |
|
|
45,097 |
|
|
|
159,980 |
|
|
180,048 |
|
Provision for doubtful
accounts |
|
6,981 |
|
|
5,855 |
|
|
|
25,059 |
|
|
19,519 |
|
Depreciation and
amortization |
|
3,984 |
|
|
5,016 |
|
|
|
17,123 |
|
|
19,678 |
|
Asset impairment
charge |
|
1,323 |
|
|
4,432 |
|
|
|
1,323 |
|
|
4,432 |
|
Securities
Class Action Lawsuit settlement, net |
|
— |
|
|
— |
|
|
|
28,712 |
|
|
— |
|
Operating expenses |
|
374,492 |
|
|
352,736 |
|
|
|
1,455,156 |
|
|
1,380,114 |
|
|
|
|
|
|
|
|
|
|
|
|
Operating income |
|
29,746 |
|
|
13,560 |
|
|
|
78,524 |
|
|
57,340 |
|
Other income
(expense): |
|
|
|
|
Interest
income |
|
54 |
|
|
30 |
|
|
|
158 |
|
|
75 |
|
Interest
expense |
|
(1,431 |
) |
|
(1,613 |
) |
|
|
(5,031 |
) |
|
(5,164 |
) |
Equity in
earnings from equity method investments |
|
232 |
|
|
1,986 |
|
|
|
3,381 |
|
|
5,588 |
|
Miscellaneous, net |
|
487 |
|
|
621 |
|
|
|
3,769 |
|
|
3,727 |
|
Total other income (expense), net |
|
(658 |
) |
|
1,024 |
|
|
|
2,277 |
|
|
4,226 |
|
|
|
|
|
|
|
|
|
|
|
|
Income before income
taxes |
|
29,088 |
|
|
14,584 |
|
|
|
80,801 |
|
|
61,566 |
|
Income tax expense |
|
(32,794 |
) |
|
(5,612 |
) |
|
|
(50,118 |
) |
|
(23,935 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
(3,706 |
) |
|
8,972 |
|
|
|
30,683 |
|
|
37,631 |
|
Net income attributable
to noncontrolling interests |
|
(142 |
) |
|
(55 |
) |
|
|
(382 |
) |
|
(370 |
) |
Net income (loss)
attributable to Amedisys, Inc. |
$ |
(3,848 |
) |
$ |
8,917 |
|
|
$ |
30,301 |
|
$ |
37,261 |
|
|
|
|
|
|
|
|
|
|
|
|
Basic
earnings per common share: |
Net
income (loss) attributable to Amedisys, Inc. common
stockholders |
$ |
(0.11 |
) |
$ |
0.27 |
|
|
$ |
0.90 |
|
$ |
1.12 |
|
Weighted
average shares outstanding |
|
33,898 |
|
|
33,365 |
|
|
|
33,704 |
|
|
33,198 |
|
Diluted
earnings per common share: |
Net
income (loss) attributable to Amedisys, Inc. common
stockholders |
$ |
(0.11 |
) |
$ |
0.26 |
|
|
$ |
0.88 |
|
$ |
1.10 |
|
Weighted
average shares outstanding |
|
33,898 |
|
|
33,866 |
|
|
|
34,304 |
|
|
33,741 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET (Amounts in
thousands, except share data)
|
|
|
|
December 31, 2017 |
|
|
December 31, 2016 |
|
ASSETS |
|
|
Current assets: |
|
|
Cash and
cash equivalents |
$ |
86,363 |
|
|
$ |
30,197 |
|
Patient
accounts receivable, net of allowance for doubtful accounts of
$20,866 and $17,716 |
|
201,196 |
|
|
|
166,056 |
|
Prepaid
expenses |
|
7,329 |
|
|
|
7,397 |
|
Other
current assets |
|
16,268 |
|
|
|
11,260 |
|
|
|
|
|
|
Total current assets |
|
311,156 |
|
|
|
214,910 |
|
Property and equipment,
net of accumulated depreciation of $146,814 and $138,650 |
|
31,122 |
|
|
|
36,999 |
|
Goodwill |
|
319,949 |
|
|
|
288,957 |
|
Intangible assets, net
of accumulated amortization of $30,610 and $27,864 |
|
46,061 |
|
|
|
46,755 |
|
Deferred income
taxes |
|
56,064 |
|
|
|
107,940 |
|
Other assets, net |
|
49,130 |
|
|
|
38,468 |
|
Total assets |
$ |
813,482 |
|
|
$ |
734,029 |
|
|
|
|
|
|
LIABILITIES AND EQUITY |
|
|
Current
liabilities: |
|
|
Accounts
payable |
$ |
25,384 |
|
|
$ |
30,358 |
|
Payroll
and employee benefits |
|
89,936 |
|
|
|
82,480 |
|
Accrued
expenses |
|
89,104 |
|
|
|
63,290 |
|
Current
portion of long-term obligations |
|
10,638 |
|
|
|
5,220 |
|
Total current liabilities |
|
215,062 |
|
|
|
181,348 |
|
Long-term obligations,
less current portion |
|
78,203 |
|
|
|
87,809 |
|
Other long-term
obligations |
|
3,791 |
|
|
|
3,730 |
|
Total liabilities |
|
297,056 |
|
|
|
272,887 |
|
|
|
|
|
|
Equity: |
|
|
Preferred
stock, $0.001 par value, 5,000,000 shares authorized; none issued
or outstanding |
|
— |
|
|
|
— |
|
Common
stock, $0.001 par value, 60,000,000 shares authorized; 35,747,134
and 35,253,577 shares issued; and 33,964,767 and
33,597,215 shares outstanding |
|
35 |
|
|
|
35 |
|
Additional paid-in capital |
|
568,780 |
|
|
|
537,472 |
|
Treasury
stock at cost, 1,782,367 and 1,656,362 shares of common stock |
|
(53,713 |
) |
|
|
(46,774 |
) |
Accumulated other comprehensive income |
|
15 |
|
|
|
15 |
|
Retained
earnings (deficit) |
|
204 |
|
|
|
(30,545 |
) |
|
|
|
|
|
Total Amedisys, Inc. stockholders’ equity |
|
515,321 |
|
|
|
460,203 |
|
Noncontrolling
interests |
|
1,105 |
|
|
|
939 |
|
Total equity |
|
516,426 |
|
|
|
461,142 |
|
Total liabilities and equity |
$ |
813,482 |
|
|
$ |
734,029 |
|
|
|
|
|
|
AMEDISYS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE
OUTSTANDING, NET (Amounts in thousands, except
statistical information)
|
|
|
|
|
|
For the Three Month Period
Ended December 31, |
|
For the Year Ended
December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
|
Cash Flows from
Operating Activities: |
|
|
|
|
Net income (loss) |
$ |
(3,706 |
) |
|
$ |
8,972 |
|
|
$ |
30,683 |
|
|
$ |
37,631 |
|
Adjustments to
reconcile net income (loss) to net cash provided by operating
activities: |
|
|
|
|
Depreciation and amortization |
|
3,984 |
|
|
|
5,016 |
|
|
|
17,123 |
|
|
|
19,678 |
|
Provision
for doubtful accounts |
|
6,981 |
|
|
|
5,855 |
|
|
|
25,059 |
|
|
|
19,519 |
|
Non-cash
compensation |
|
4,507 |
|
|
|
3,845 |
|
|
|
16,295 |
|
|
|
16,401 |
|
401(k)
employer match |
|
2,207 |
|
|
|
1,741 |
|
|
|
8,754 |
|
|
|
6,875 |
|
Write-off
of investment |
|
— |
|
|
|
196 |
|
|
|
— |
|
|
|
196 |
|
Loss on
disposal of property and equipment |
|
22 |
|
|
|
26 |
|
|
|
— |
|
|
|
582 |
|
Deferred
income taxes |
|
34,950 |
|
|
|
5,858 |
|
|
|
52,178 |
|
|
|
24,547 |
|
Equity in
earnings from equity method investments |
|
(232 |
) |
|
|
(1,986 |
) |
|
|
(3,381 |
) |
|
|
(5,588 |
) |
Amortization of deferred debt issuance costs |
|
180 |
|
|
|
185 |
|
|
|
735 |
|
|
|
740 |
|
Return on
equity investment |
|
665 |
|
|
|
2,410 |
|
|
|
5,321 |
|
|
|
4,323 |
|
Asset
impairment charge |
|
1,323 |
|
|
|
4,432 |
|
|
|
1,323 |
|
|
|
4,432 |
|
Changes in operating
assets and liabilities, net of impact of acquisitions: |
|
|
|
|
Patient
accounts receivable |
|
(30,807 |
) |
|
|
(9,412 |
) |
|
|
(59,731 |
) |
|
|
(55,519 |
) |
Other
current assets |
|
956 |
|
|
|
3,361 |
|
|
|
(4,940 |
) |
|
|
4,231 |
|
Other
assets |
|
(547 |
) |
|
|
494 |
|
|
|
(12,749 |
) |
|
|
(11,415 |
) |
Accounts
payable |
|
2,587 |
|
|
|
(3,338 |
) |
|
|
(2,843 |
) |
|
|
3,970 |
|
Accrued
expenses |
|
9,259 |
|
|
|
1,482 |
|
|
|
31,843 |
|
|
|
(7,618 |
) |
Other
long-term obligations |
|
(140 |
) |
|
|
(576 |
) |
|
|
61 |
|
|
|
(726 |
) |
Net cash provided by
operating activities |
|
32,189 |
|
|
|
28,561 |
|
|
|
105,731 |
|
|
|
62,259 |
|
|
|
|
|
|
Cash Flows from
Investing Activities: |
|
|
|
|
Proceeds
from sale of deferred compensation plan assets |
|
— |
|
|
|
— |
|
|
|
622 |
|
|
|
230 |
|
Proceeds
from sale of property and equipment |
|
131 |
|
|
|
— |
|
|
|
249 |
|
|
|
— |
|
Purchases
of property and equipment |
|
(1,633 |
) |
|
|
(2,215 |
) |
|
|
(10,707 |
) |
|
|
(15,717 |
) |
Purchase
of investments |
|
(40 |
) |
|
|
(290 |
) |
|
|
(476 |
) |
|
|
(1,040 |
) |
Acquisitions of businesses, net of cash acquired |
|
(9,587 |
) |
|
|
(4,144 |
) |
|
|
(33,715 |
) |
|
|
(35,522 |
) |
Net cash used in
investing activities |
|
(11,129 |
) |
|
|
(6,649 |
) |
|
|
(44,027 |
) |
|
|
(52,049 |
) |
|
|
|
|
|
Cash Flows from
Financing Activities: |
|
|
|
|
Proceeds
from issuance of stock upon exercise of stock options and
warrants |
|
340 |
|
|
|
— |
|
|
|
4,554 |
|
|
|
— |
|
Proceeds
from issuance of stock to employee stock purchase plan |
|
584 |
|
|
|
665 |
|
|
|
2,382 |
|
|
|
2,483 |
|
Shares
withheld upon stock vesting |
|
(485 |
) |
|
|
— |
|
|
|
(6,939 |
) |
|
|
— |
|
Tax
benefit from stock options exercised and restricted stock
vesting |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
7,241 |
|
Non-controlling interest distribution |
|
— |
|
|
|
(45 |
) |
|
|
(216 |
) |
|
|
(329 |
) |
Proceeds
from revolving line of credit |
|
— |
|
|
|
6,000 |
|
|
|
— |
|
|
|
134,500 |
|
Repayments of revolving line of credit |
|
— |
|
|
|
(6,000 |
) |
|
|
— |
|
|
|
(134,500 |
) |
Principal
payments of long-term obligations |
|
(1,250 |
) |
|
|
(1,250 |
) |
|
|
(5,319 |
) |
|
|
(5,000 |
) |
Purchase
of company stock |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(12,315 |
) |
Assets
contributed to equity investment |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
405 |
|
Net cash used in
financing activities |
|
(811 |
) |
|
|
(630 |
) |
|
|
(5,538 |
) |
|
|
(7,515 |
) |
Net increase in cash
and cash equivalents |
|
20,249 |
|
|
|
21,282 |
|
|
|
56,166 |
|
|
|
2,695 |
|
Cash and cash
equivalents at beginning of period |
|
66,114 |
|
|
|
8,915 |
|
|
|
30,197 |
|
|
|
27,502 |
|
Cash and cash
equivalents at end of period |
$ |
86,363 |
|
|
$ |
30,197 |
|
|
$ |
86,363 |
|
|
$ |
30,197 |
|
|
|
|
|
|
Supplemental
Disclosures of Cash Flow Information: |
|
|
|
|
Cash paid for
interest |
$ |
509 |
|
|
$ |
621 |
|
|
$ |
2,697 |
|
|
$ |
2,897 |
|
Cash paid for income
taxes, net of refunds received |
$ |
— |
|
|
$ |
(3 |
) |
|
$ |
315 |
|
|
$ |
755 |
|
Days
revenue outstanding, net (1) |
|
44.0 |
|
|
|
40.2 |
|
|
|
44.0 |
|
|
|
40.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Our calculation of days revenue outstanding, net at
December 31, 2017 and 2016 is derived by dividing our ending
patient accounts receivable (i.e., net of estimated revenue
adjustments and allowance for doubtful accounts) by our average
daily net patient revenue for the three month periods ended
December 31, 2017 and 2016, respectively.
AMEDISYS, INC. AND SUBSIDIARIES
SEGMENT INFORMATION (Amounts in millions,
except statistical information)
(Unaudited)
Segment Information - Home
Health
|
|
|
|
For the Three Month Period Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Medicare |
$ |
205.0 |
|
|
$ |
203.2 |
|
Non-Medicare |
|
82.3 |
|
|
|
65.1 |
|
Net
service revenue |
|
287.3 |
|
|
|
268.3 |
|
Cost of service |
|
174.9 |
|
|
|
160.1 |
|
Gross margin |
|
112.4 |
|
|
|
108.2 |
|
Provision for doubtful
accounts |
|
5.4 |
|
|
|
3.1 |
|
Asset impairment
charge |
|
1.3 |
|
|
|
— |
|
Other operating
expenses |
|
71.3 |
|
|
|
69.6 |
|
Operating income |
$ |
34.4 |
|
|
$ |
35.5 |
|
|
|
|
Same Store
Growth (1): |
|
|
Medicare revenue |
|
2 |
% |
|
|
(1 |
%) |
Non-Medicare
revenue |
|
26 |
% |
|
|
(2 |
%) |
Medicare
admissions |
|
(2 |
%) |
|
|
2 |
% |
Total Episodic
admissions |
|
2 |
% |
|
|
4 |
% |
Total Episodic
volume |
|
5 |
% |
|
|
3 |
% |
Total admissions |
|
3 |
% |
|
|
- |
% |
|
|
|
Key Statistical
Data - Total (2): |
|
|
Medicare: |
|
|
Admissions |
|
46,421 |
|
|
|
47,637 |
|
Recertifications |
|
27,896 |
|
|
|
25,628 |
|
Total volume |
|
74,317 |
|
|
|
73,265 |
|
|
|
|
Completed episodes |
|
73,037 |
|
|
|
71,855 |
|
Visits |
|
1,273,435 |
|
|
|
1,230,434 |
|
Average revenue per
completed episode (3) |
$ |
2,858 |
|
|
$ |
2,851 |
|
Visits per completed
episode (4) |
|
17.6 |
|
|
|
17.2 |
|
|
|
|
Non-Medicare: |
|
|
Admissions |
|
27,421 |
|
|
|
24,309 |
|
Recertifications |
|
12,415 |
|
|
|
9,673 |
|
Visits |
|
619,745 |
|
|
|
501,215 |
|
Total
(2): |
|
|
Visiting Clinician Cost
per Visit |
$ |
83.88 |
|
|
$ |
83.46 |
|
Clinical Manager Cost
per Visit |
$ |
8.49 |
|
|
$ |
9.01 |
|
Total Cost per
Visit |
$ |
92.37 |
|
|
$ |
92.47 |
|
Visits |
|
1,893,180 |
|
|
|
1,731,649 |
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Medicare |
$ |
793.3 |
|
|
$ |
822.4 |
|
Non-Medicare |
|
308.5 |
|
|
|
263.1 |
|
Net
service revenue |
|
1,101.8 |
|
|
|
1,085.5 |
|
Cost of service |
|
670.9 |
|
|
|
643.7 |
|
Gross margin |
|
430.9 |
|
|
|
441.8 |
|
Provision for doubtful
accounts |
|
17.9 |
|
|
|
13.8 |
|
Asset impairment
charge |
|
1.3 |
|
|
|
— |
|
Other operating
expenses |
|
281.9 |
|
|
|
289.4 |
|
Operating income |
$ |
129.8 |
|
|
$ |
138.6 |
|
|
|
|
Same Store
Growth (1): |
|
|
Medicare revenue |
|
(4 |
%) |
|
|
2 |
% |
Non-Medicare
revenue |
|
17 |
% |
|
|
8 |
% |
Medicare
admissions |
|
(2 |
%) |
|
|
3 |
% |
Total Episodic
admissions |
|
1 |
% |
|
|
4 |
% |
Total Episodic
volume |
|
3 |
% |
|
|
3 |
% |
Total admissions |
|
2 |
% |
|
|
2 |
% |
|
|
|
Key Statistical
Data - Total (2): |
|
|
Medicare: |
|
|
Admissions |
|
190,132 |
|
|
|
194,662 |
|
Recertifications |
|
106,774 |
|
|
|
103,193 |
|
Total volume |
|
296,906 |
|
|
|
297,855 |
|
|
|
|
Completed episodes |
|
290,227 |
|
|
|
289,862 |
|
Visits |
|
5,067,436 |
|
|
|
5,124,002 |
|
Average revenue per
completed episode (3) |
$ |
2,823 |
|
|
$ |
2,839 |
|
Visits per completed
episode (4) |
|
17.3 |
|
|
|
17.5 |
|
|
|
|
Non-Medicare: |
|
|
Admissions |
|
107,665 |
|
|
|
98,448 |
|
Recertifications |
|
46,364 |
|
|
|
38,618 |
|
Visits |
|
2,347,363 |
|
|
|
2,050,975 |
|
|
|
|
Total
(2): |
|
|
Visiting Clinician Cost
per Visit |
$ |
82.04 |
|
|
$ |
81.18 |
|
Clinical Manager Cost
per Visit |
$ |
8.44 |
|
|
$ |
8.53 |
|
Total Cost per
Visit |
$ |
90.48 |
|
|
$ |
89.71 |
|
Visits |
|
7,414,799 |
|
|
|
7,174,977 |
|
|
|
|
|
|
|
|
|
(1) Same store information represents the percent increase
(decrease) in our Medicare and Non-Medicare revenue, admissions or
volume for the period as a percent of the Medicare and Non-Medicare
revenue, admissions or volume of the prior period. (2) Total
includes acquisitions. (3) Average Medicare revenue per completed
episode is the average Medicare revenue earned for each Medicare
completed episode of care. (4) Medicare visits per completed
episode are the home health Medicare visits on completed episodes
divided by the home health Medicare episodes completed during the
period.
Segment Information -
Hospice
|
|
|
|
For the Three Month Period Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Medicare |
$ |
92.7 |
|
|
$ |
80.7 |
|
Non-Medicare |
|
5.5 |
|
|
|
4.5 |
|
Net
service revenue |
|
98.2 |
|
|
|
85.2 |
|
Cost of service |
|
49.9 |
|
|
|
43.0 |
|
|
|
|
Gross margin |
|
48.3 |
|
|
|
42.2 |
|
Provision for doubtful
accounts |
|
1.0 |
|
|
|
2.7 |
|
Other operating
expenses |
|
20.8 |
|
|
|
18.7 |
|
Operating income |
$ |
26.5 |
|
|
$ |
20.8 |
|
|
|
|
Same Store
Growth (1): |
|
|
Medicare revenue |
|
14 |
% |
|
|
14 |
% |
Non-Medicare
revenue |
|
20 |
% |
|
|
(7 |
%) |
Hospice admissions |
|
8 |
% |
|
|
16 |
% |
Average daily
census |
|
12 |
% |
|
|
13 |
% |
Key Statistical
Data - Total (2): |
|
|
Hospice admissions |
|
6,371 |
|
|
|
5,769 |
|
Average daily
census |
|
7,162 |
|
|
|
6,318 |
|
Revenue per day,
net |
$ |
149.12 |
|
|
$ |
146.56 |
|
Cost of service per
day |
$ |
75.74 |
|
|
$ |
73.91 |
|
Average discharge
length of stay |
|
96 |
|
|
|
99 |
|
|
|
|
For the Year Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Medicare |
$ |
350.7 |
|
|
$ |
297.7 |
|
Non-Medicare |
|
20.3 |
|
|
|
18.3 |
|
Net
service revenue |
|
371.0 |
|
|
|
316.0 |
|
Cost of service |
|
184.8 |
|
|
|
163.1 |
|
|
|
|
Gross margin |
|
186.2 |
|
|
|
152.9 |
|
Provision for doubtful
accounts |
|
5.9 |
|
|
|
5.5 |
|
Other operating
expenses |
|
77.5 |
|
|
|
71.5 |
|
Operating income |
$ |
102.8 |
|
|
$ |
75.9 |
|
|
|
|
Same Store
Growth (1): |
|
|
Medicare revenue |
|
17 |
% |
|
|
15 |
% |
Non-Medicare
revenue |
|
10 |
% |
|
|
9 |
% |
Hospice admissions |
|
11 |
% |
|
|
17 |
% |
Average daily
census |
|
15 |
% |
|
|
16 |
% |
Key Statistical
Data -Total (2): |
|
|
Hospice admissions |
|
25,381 |
|
|
|
22,526 |
|
Average daily
census |
|
6,820 |
|
|
|
5,912 |
|
Revenue per day,
net |
$ |
149.04 |
|
|
$ |
146.05 |
|
Cost of service per
day |
$ |
74.25 |
|
|
$ |
75.36 |
|
Average discharge
length of stay |
|
93 |
|
|
|
96 |
|
|
|
|
|
|
|
|
|
(1) Same store information represents the percent increase
(decrease) in our Medicare and Non-Medicare revenue, Hospice
admissions or average daily census for the period as a percent of
the Medicare and Non-Medicare revenue, Hospice admissions or
average daily census of the prior period. (2) Total includes
acquisitions.
Segment Information - Personal
Care
|
|
|
|
For the Three Month Period Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Medicare |
$ |
— |
|
$ |
— |
Non-Medicare |
|
18.7 |
|
|
12.7 |
Net
service revenue |
|
18.7 |
|
|
12.7 |
Cost of service |
|
13.7 |
|
|
9.5 |
|
|
|
Gross margin |
|
5.0 |
|
|
3.2 |
Provision for doubtful
accounts |
|
0.6 |
|
|
0.1 |
Other operating
expenses |
|
4.4 |
|
|
2.8 |
Operating income |
$ |
0.0 |
|
$ |
0.3 |
|
|
|
Key Statistical
Data: |
|
|
Billable hours |
|
782,140 |
|
|
548,703 |
Clients served |
|
12,693 |
|
|
7,392 |
Shifts |
|
365,360 |
|
|
245,535 |
Revenue per hour |
$ |
23.94 |
|
$ |
23.16 |
Revenue per shift |
$ |
51.26 |
|
$ |
51.75 |
Hours per shift |
|
2.1 |
|
|
2.2 |
|
|
|
For the Year Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Medicare |
$ |
— |
|
$ |
— |
Non-Medicare |
|
60.9 |
|
|
35.9 |
Net
service revenue |
|
60.9 |
|
|
35.9 |
Cost of service |
|
45.0 |
|
|
26.3 |
|
|
|
Gross margin |
|
15.9 |
|
|
9.6 |
Provision for doubtful
accounts |
|
1.3 |
|
|
0.2 |
Other operating
expenses |
|
13.8 |
|
|
7.9 |
Operating income |
$ |
0.8 |
|
$ |
1.5 |
|
|
|
Key Statistical
Data: |
|
|
Billable hours |
|
2,604,794 |
|
|
1,539,093 |
Clients served |
|
16,826 |
|
|
10,219 |
Shifts |
|
1,195,511 |
|
|
696,956 |
Revenue per hour |
$ |
23.37 |
|
$ |
23.32 |
Revenue per shift |
$ |
50.92 |
|
$ |
51.49 |
Hours per shift |
|
2.2 |
|
|
2.2 |
|
|
|
|
|
|
Segment Information - Corporate
|
|
|
|
For the Three Month Period Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Other operating
expenses |
$ |
28.3 |
|
$ |
35.5 |
Depreciation and
amortization |
|
2.9 |
|
|
3.1 |
Total operating
expenses before asset impairment charge |
|
31.2 |
|
|
38.6 |
Asset impairment
charge |
|
— |
|
|
4.4 |
Total operating
expenses |
$ |
31.2 |
|
$ |
43.0 |
|
|
|
|
|
|
For the Year Ended December 31,
|
|
2017 |
|
2016 |
Financial
Information (in millions): |
|
|
Other operating
expenses |
$ |
113.7 |
|
$ |
141.9 |
Depreciation and
amortization |
|
12.5 |
|
|
12.4 |
Total operating
expenses before asset impairment charge and Securities
Class Action Lawsuit settlement, net |
|
126.2 |
|
|
154.3 |
Asset impairment
charge |
|
— |
|
|
4.4 |
Securities
Class Action Lawsuit settlement, net |
|
28.7 |
|
|
— |
Total operating
expenses |
$ |
154.9 |
|
$ |
158.7 |
|
|
|
AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP
MEASURES (Amounts in thousands)
(Unaudited)
Adjusted Earnings Before Interest, Taxes, Depreciation
and Amortization (“Adjusted EBITDA”):
|
|
|
|
|
|
For the Three Month Period
Ended December 31, |
|
For the Year Ended December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
Net income (loss)
attributable to Amedisys, Inc. |
$ |
(3,848 |
) |
|
$ |
8,917 |
|
|
$ |
30,301 |
|
|
$ |
37,261 |
|
Add: |
|
|
|
|
Income
tax expense |
|
32,794 |
|
|
|
5,612 |
|
|
|
50,118 |
|
|
|
23,935 |
|
Interest
expense, net |
|
1,377 |
|
|
|
1,583 |
|
|
|
4,873 |
|
|
|
5,089 |
|
Depreciation and amortization |
|
3,984 |
|
|
|
5,016 |
|
|
|
17,123 |
|
|
|
19,678 |
|
Certain
items (1) |
|
24,414 |
|
|
|
9,999 |
|
|
|
61,429 |
|
|
|
24,559 |
|
Interest
component of certain items (1) |
|
(168 |
) |
|
|
(625 |
) |
|
|
(263 |
) |
|
|
(625 |
) |
Tax
component of certain items (1) |
|
(21,424 |
) |
|
|
— |
|
|
|
(21,424 |
) |
|
|
— |
|
Adjusted EBITDA (2)
(6) |
$ |
37,129 |
|
|
$ |
30,502 |
|
|
$ |
142,157 |
|
|
$ |
109,897 |
|
|
|
|
|
|
Adjusted Net Service Revenue
Reconciliation:
|
|
|
|
|
|
For the Three Month Period
Ended December 31, |
|
For the Year Ended December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
Net service
revenue |
$ |
404,238 |
|
$ |
366,296 |
|
|
$ |
1,533,680 |
|
$ |
1,437,454 |
|
Add: |
|
|
|
|
Certain
items (1) |
|
— |
|
|
(1,149 |
) |
|
|
6,506 |
|
|
(201 |
) |
Adjusted net service
revenue (3) (6) |
$ |
404,238 |
|
$ |
365,147 |
|
|
$ |
1,540,186 |
|
$ |
1,437,253 |
|
|
|
|
|
|
Adjusted Net Income Attributable to Amedisys, Inc.
Reconciliation:
|
|
|
|
|
|
For the Three Month Period
Ended December 31, |
|
For the Year Ended December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
Net income (loss)
attributable to Amedisys, Inc. |
$ |
(3,848 |
) |
|
$ |
8,917 |
|
$ |
30,301 |
|
$ |
37,261 |
Add: |
|
|
|
|
Certain
items (1) |
|
23,233 |
|
|
|
6,114 |
|
|
45,627 |
|
|
14,923 |
Adjusted net income
attributable to Amedisys, Inc. (4) (6) |
$ |
19,385 |
|
|
$ |
15,031 |
|
$ |
75,928 |
|
$ |
52,184 |
|
|
|
|
|
Adjusted Net Income Attributable to Amedisys, Inc. per
Diluted Share:
|
|
|
|
|
|
For the Three Month Period
Ended December 31, |
|
For the Year Ended December 31, |
|
2017 |
|
2016 |
|
2017 |
|
2016 |
Net income (loss)
attributable to Amedisys, Inc. common
stockholders per diluted share |
$ |
(0.11 |
) |
|
$ |
0.26 |
|
$ |
0.88 |
|
$ |
1.10 |
Add: |
|
|
|
|
Certain
items (1) |
|
0.67 |
|
|
|
0.18 |
|
|
1.33 |
|
|
0.44 |
|
|
|
|
|
Adjusted net income
attributable to Amedisys, Inc. common
stockholders per diluted share (5) (6) |
$ |
0.56 |
|
|
$ |
0.44 |
|
$ |
2.21 |
|
$ |
1.55 |
|
|
|
|
|
(1) The following details the
certain items for the three month periods and years ended
December 31, 2017 and 2016:
Certain Items:
|
|
|
|
For the Three Month Period
Ended December 31, 2017 |
|
For the Year Ended
December 31, 2017 |
|
(Income) Expense |
|
(Income) Expense |
Certain Items
Impacting Net Service Revenue: |
|
|
Florida ZPIC audit |
$ |
— |
|
|
$ |
6,506 |
|
Certain Items
Impacting Operating Expenses: |
|
|
Acquisition costs |
|
48 |
|
|
|
1,025 |
|
Legal fees -
non-routine |
|
358 |
|
|
|
1,768 |
|
Securities
Class Action Lawsuit settlement, net |
|
— |
|
|
|
28,712 |
|
Restructuring
activity |
|
648 |
|
|
|
2,318 |
|
Data center
relocation |
|
— |
|
|
|
940 |
|
Asset impairment |
|
1,323 |
|
|
|
1,323 |
|
Certain Items
Impacting Total Other Income (Expense): |
|
|
Legal settlements |
|
— |
|
|
|
(2,014 |
) |
Miscellaneous, other
(income) expense, net |
|
613 |
|
|
|
(573 |
) |
Certain Items
Impacting Income Tax Expense: |
|
|
Remeasurement of
deferred tax assets and liabilities |
|
21,424 |
|
|
|
21,424 |
|
|
|
|
Total |
$ |
24,414 |
|
|
$ |
61,429 |
|
|
|
|
Net of tax |
$ |
23,233 |
|
|
$ |
45,627 |
|
|
|
|
Diluted EPS |
$ |
0.67 |
|
|
$ |
1.33 |
|
|
|
|
|
|
|
|
For the Three Month Period Ended
December 31, 2016 |
|
For the Year Ended December 31,
2016 |
|
(Income) Expense |
|
(Income) Expense |
Certain Items
Impacting Net Service Revenue: |
|
|
Reduction of cost
report reserve |
$ |
(1,149 |
) |
|
$ |
(1,149 |
) |
Third party audit
reserve |
|
— |
|
|
|
948 |
|
Certain Items
Impacting Operating Expenses: |
|
|
HCHB
implementation |
|
1,345 |
|
|
|
8,371 |
|
Acquisition costs |
|
876 |
|
|
|
3,384 |
|
Legal fees -
non-routine |
|
543 |
|
|
|
1,992 |
|
Frontier
litigation |
|
2,479 |
|
|
|
2,979 |
|
Wage and Hour
litigation |
|
(119 |
) |
|
|
282 |
|
Asset impairment |
|
4,432 |
|
|
|
4,432 |
|
Restructuring
activity |
|
1,976 |
|
|
|
7,645 |
|
Sales/use tax audit
reserve |
|
460 |
|
|
|
460 |
|
Disaster relief |
|
129 |
|
|
|
467 |
|
Certain Items
Impacting Total Other Income (Expense): |
|
|
Sales/use tax audit
reserve |
|
625 |
|
|
|
625 |
|
Legal settlements |
|
(280 |
) |
|
|
(2,328 |
) |
Miscellaneous, other
(income) expense, net |
|
(1,318 |
) |
|
|
(3,549 |
) |
|
|
|
Total |
$ |
9,999 |
|
|
$ |
24,559 |
|
|
|
|
Net of tax |
$ |
6,114 |
|
|
$ |
14,923 |
|
|
|
|
Diluted EPS |
$ |
0.18 |
|
|
$ |
0.44 |
|
|
|
|
(2) Adjusted EBITDA is defined as
net income (loss) attributable to Amedisys, Inc. before provision
for income taxes, net interest expense and depreciation and
amortization, excluding certain items as described in footnote 1.
(3) Adjusted net service revenue is
defined as net service revenue plus certain items as described in
footnote 1. (4) Adjusted net income
attributable to Amedisys, Inc. is defined as net income (loss)
attributable to Amedisys, Inc. calculated in accordance with GAAP
excluding certain items as described in footnote 1.
(5) Adjusted net income attributable
to Amedisys, Inc. common stockholders per diluted share is defined
as diluted income (loss) per share calculated in accordance with
GAAP excluding the earnings per share effect of certain items as
described in footnote 1. (6) Adjusted
EBITDA, adjusted net service revenue, adjusted net income
attributable to Amedisys, Inc. and adjusted net income attributable
to Amedisys, Inc. common stockholders per diluted share should not
be considered as an alternative to, or more meaningful than, income
before income taxes or other measure calculated in accordance with
GAAP. These calculations may not be comparable to a similarly
titled measure reported by other companies, since not all companies
calculate these non-GAAP financial measures in the same manner.
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2023 to Apr 2024